Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL)

Enabling Phase 3 DAYBreak CLL-306 bexobrutideg confirmatory trial for full approval in r/r CLL

Targeting 2026 IND submission for bexobrutideg in inflammatory and autoimmune indications with a new tablet formulation

Continuing advancement of targeted protein degraders of IRAK4 in Phase 1 and STAT6 in IND-enabling studies under strategic partnerships

Well capitalized with $540.7 million on the balance sheet

BRISBANE, Calif., April 08, 2026 — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today reported financial results for the fiscal quarter ended February 28, 2026, and highlighted continued execution across its registrational program for bexobrutideg, advancement of its broader pipeline, and multiple anticipated clinical and scientific catalysts in 2026.

“Nurix entered 2026 focused on implementing a comprehensive registrational program designed to establish bexobrutideg as a potential best-in-class medicine for patients with chronic lymphocytic leukemia,” said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. “Building on compelling clinical data in oncology, we are also completing a series of healthy volunteer studies to support bexobrutideg’s development in selected immunology and inflammation indications where removal of the BTK protein through targeted protein degradation could offer advantages over BTK inhibitor drugs. Together with the advancement of our partnered degraders of STAT6 with Sanofi and IRAK-4 with Gilead, Nurix’s pipeline includes some of the most exciting new targets in the industry with the potential to address a wide spectrum of autoimmune diseases.”

Program Highlights*

Bexobrutideg

Bexobrutideg is an investigational, orally bioavailable, brain penetrant, highly selective small molecule degrader of BTK for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases.

• DAYBreak CLL-201 Enrollment is ongoing in the DAYBreak CLL-201 pivotal Phase 2 single-arm study (NCT07221500) in patients with r/r CLL, which is designed to support a potential Accelerated Approval submission. The study is enrolling patients whose disease has progressed following treatment with a cBTKi, a BCL-2i, and an ncBTKi inhibitor, representing a population with significant unmet medical need. More information on the Phase 2 trial is available at www.clinicaltrials.gov.
• DAYBreak CLL-306 Nurix plans to initiate a global randomized confirmatory Phase 3 trial by midyear 2026 to support full approval. The Phase 3 study will compare once daily bexobrutideg monotherapy to the most recently approved non-covalent inhibitor, pirtobrutinib, in patients with r/r CLL whose disease has progressed after prior BTK inhibitor therapy.
• NX-5948-301 Nurix continues to enroll select cohorts in the NX-5948-301 Phase 1a/1b clinical trial (NCT05131022) in patients with relapsed or refractory B cell malignancies. The Phase 1b study includes cohorts testing the safety and efficacy of the 600 mg dose of bexobrutideg in earlier lines of therapy in CLL patients. Updated data from this study are anticipated to be presented at upcoming medical meetings throughout 2026. More information on the ongoing Phase 1a/1b trial of bexobrutideg is available at www.clinicaltrials.gov.
• Healthy volunteer SAD/MAD study Nurix is conducting a Phase 1 single ascending and multiple ascending dose (SAD/MAD) study (NCT06717269) to evaluate pharmacokinetics (PK), pharmacodynamics (PD), and safety of a new tablet formulation of bexobrutideg. This study is intended to support an IND filing and enable expansion into immunology and inflammation indications in 2026. More information on the Phase 1 SAD/MAD trial of bexobrutideg is available at www.clinicaltrials.gov.

Zelebrudomide

Zelebrudomide is an orally bioavailable degrader of BTK and the cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) designed for the treatment of relapsed or refractory B-cell malignancies. Nurix is conducting a Phase 1a/1b clinical trial (NCT04830137), including a Phase 1b expansion cohort focused on patients with diffuse large B-cell lymphoma and mantle cell lymphoma. Nurix is enrolling in the dose escalation cohort of the Phase 1a/1b trial using the chirally controlled drug product. Additional information on the zelebrudomide clinical trial can be accessed at www.clinicaltrials.gov.

NX-1607

NX-1607 is an investigational oral inhibitor of the E3 ligase Casitas B-lineage lymphoma proto-oncogene B (CBL-B) being developed for immuno-oncology indications, including a range of solid tumor types and lymphomas. Nurix is evaluating NX-1607 in an ongoing Phase 1 trial (NCT05107674) in adults in a range of oncology indications. This study includes a thorough investigation of both dose and schedule in the Phase 1a portion. Additional information on the NX-1607 clinical trial can be accessed at www.clinicaltrials.gov.

Strategic collaborations with Gilead, Sanofi and Pfizer

Sanofi continues to advance the STAT6 degrader, NX-3911, in IND-enabling studies. Nurix retains the right to opt-in after clinical proof of concept to a 50/50 U.S. profit share and co-development agreement. Gilead continues to advance the IRAK4 degrader, GS-6791, in an ongoing first-in-human Phase 1 study in healthy volunteers. Nurix retains the right to opt-in after Phase 1 to a 50/50 U.S. profit share and co-development, subject to certain restriction. Nurix anticipates the achievement of substantial research collaboration milestones throughout the terms of its collaborations with Gilead, Sanofi, and Pfizer.

*Expected timing of events throughout this press release is based on calendar year quarters.

Fiscal First Quarter 2026 Financial Results

Revenue for the three months ended February 28, 2026, was $6.3 million compared with $18.5 million for the three months ended February 28, 2025. Revenue from the collaboration with Sanofi decreased as the initial research term for certain drug targets ended.

Research and development expenses for the three months ended February 28, 2026, were $84.1 million compared with $69.7 million for the three months ended February 28, 2025. The increase was primarily related to compensation and related personnel costs, clinical costs and contract manufacturing costs as Nurix continued to accelerate the enrollment of patients in the ongoing Phase 2 trial of bexobrutideg and enable the initiation of Phase 3 trials.

General and administrative expenses for the three months ended February 28, 2026, were $14.6 million compared with $11.7 million for the three months ended February 28, 2025. The increase was primarily due to an increase in compensation and related personnel costs.

Net loss for the three months ended February 28, 2026, was $87.2 million or ($0.79) per share compared with $56.4 million or ($0.67) per share for the three months ended February 28, 2025.

Cash, cash equivalents and marketable securitieswere $540.7 million as of February 28, 2026, compared to $592.9 million as of November 30, 2025.

About Nurix Therapeutics, Inc.

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of a preclinical stage degrader of STAT6 in collaboration with Sanofi, a clinical stage degrader of IRAK4 in collaboration with Gilead, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by an AI-integrated discovery engine capable of tackling virtually any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in Brisbane, California. For additional information visit http://www.nurixtx.com.

Contacts

Investors

Kris Fortner Nurix Therapeutics, Inc. [email protected]

Sylvia Wheeler Wheelhouse Life Science Advisors [email protected]

Media

Aljanae Reynolds Wheelhouse Life Science Advisors [email protected]

Kris Fortner Nurix Therapeutics, Inc. [email protected]

--MORE--

Nurix Therapeutics, Inc. Condensed Statements of Operations (in thousands, except share and per share amounts) (unaudited)

Three Months Ended February 28,

2026

2025

Revenue:

Collaboration revenue

$

6,252

$

18,453

Total revenue

6,252

18,453

Operating expenses:

Research and development

84,137

69,663

General and administrative

14,610

11,654

Total operating expenses

98,747

81,317

Loss from operations

(92,495)

(62,864)

Interest and other income, net

5,321

6,513

Net loss

$

(87,174)

$

(56,351)

Net loss per share, basic and diluted

$

(0.79)

$

(0.67)

Weighted-average number of shares outstanding, basic and diluted

110,071,668

83,560,795

Nurix Therapeutics, Inc. Condensed Balance Sheets (in thousands) (unaudited)

February 28,

November 30,

2026

2025

Assets

Current assets:

Cash and cash equivalents

$

71,195

$

246,960

Marketable securities

469,537

345,981

Prepaid expenses and other current assets

13,662

13,878

Total current assets

554,394

606,819

Operating lease right-of-use assets

51,657

50,517

Property and equipment, net

21,697

22,490

Restricted cash

968

968

Other assets

7,414

7,341

Total assets

$

636,130

$

688,135

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable

$

10,293

$

11,215

Accrued expenses and other current liabilities

59,950

54,852

Operating lease liabilities, current

3,202

2,824

Deferred revenue, current

18,754

17,580

Total current liabilities

92,199

86,471

Operating lease liabilities, net of current portion

55,453

52,906

Deferred revenue, net of current portion

7,585

10,011

Total liabilities

155,237

149,388

Stockholders’ equity:

Common stock

103

102

Additional paid-in-capital

1,571,134

1,541,766

Accumulated other comprehensive income

56

105

Accumulated deficit

(1,090,400

)

(1,003,226

)

Total stockholders’ equity

480,893

538,747

Total liabilities and stockholders’ equity

$

636,130

$

688,135